CO6241125A2 - Moduladores de gamma secretasa - Google Patents
Moduladores de gamma secretasaInfo
- Publication number
- CO6241125A2 CO6241125A2 CO09137088A CO09137088A CO6241125A2 CO 6241125 A2 CO6241125 A2 CO 6241125A2 CO 09137088 A CO09137088 A CO 09137088A CO 09137088 A CO09137088 A CO 09137088A CO 6241125 A2 CO6241125 A2 CO 6241125A2
- Authority
- CO
- Colombia
- Prior art keywords
- cycloalkyl
- heterocyclyl
- moieties
- group
- unsubstituted
- Prior art date
Links
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
1.- Un compuesto, o las sales, solvatos, ésteres o profármacos farmacéuticamente aceptables de dicho compuesto, teniendo dicho compuesto la estructura general mostrada en la fórmula:donde: ya sea (i) R2 y R6 están unidos entre si para formar un resto cicloalquilo C4-C8, cicloalquenilo C4-C8, heterociclilo de 5-8 miembros o heterociclenilo de 5-8 miembros, estando cada uno de dichos restos cicloalquilo o heterociclilo sin sustituir u opcional e independientemente sustituido con 1-5 sustituyentes los cuales pueden ser iguales o diferentes, estando cada sustituyente seleccionado independientemente del grupo formado por los restos mostrados más adelante; o (ii) R2 y R6 están unidos entre si para formar un resto cicloalquilo C4-C8, cicloalquenilo C4-C8, heterociclilo de 5-8 miembros o heterociclenilo de 5-8 miembros, estando cada uno de dichos restos cicloalquilo o heterociclilo sin sustituir u opcional e independientemente sustituido con 1-5 sustituyentes los cuales pueden ser iguales o diferentes, estando cada sustituyente seleccionado independientemente del grupo formado por los restos mostrados más adelante; y R6 y R7 están unidos entre si para formar un resto cicloalquilo C4-C8, cicloalquenilo C4-C8, heterociclilo de 5-8 miembros o heterociclenilo de 5-8 miembros, estando cada uno de dichos restos cicloalquilo o heterociclilo sin sustituir u opcional e independientemente sustituido con 1-5 sustituyentes los cuales pueden ser iguales o diferentes, estando cada sustituyente seleccionado independientemente del grupo formado por los restos mostrados más adelante; yG es O u S; V se selecciona del grupo que comprende un enlace, O, -C(O)-, y N(R14); R1, R5 y R7 (cuando R7 no está unido a R6) pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo formado por H, alquilo-, alquenilo-, alquinilo-, arilo-, arilalquilo-, alquilarilo-, cicloalquilo-, cicloalquilalquilo-, heteroarilo-, heteroarilalquilo-, heterociclilo- y heterociclilalquilo-, donde cada uno de dichos alquilo-, alquenilo-, alquinilo-, arilo-, arilalquilo-, alquilarilo-, cicloalquilo-, cicloalquilalquilo-, heteroarilo-, heteroarilalquilo-, heterociclilo- y heterociclilalquilo- pueden estar sin sustituir ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94139607P | 2007-06-01 | 2007-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6241125A2 true CO6241125A2 (es) | 2011-01-20 |
Family
ID=40130388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09137088A CO6241125A2 (es) | 2007-06-01 | 2009-12-01 | Moduladores de gamma secretasa |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8580956B2 (es) |
| EP (1) | EP2164852A2 (es) |
| JP (1) | JP2010529014A (es) |
| KR (1) | KR20100021633A (es) |
| CN (1) | CN101932578A (es) |
| AR (1) | AR066151A1 (es) |
| AU (1) | AU2008263206A1 (es) |
| BR (1) | BRPI0812491A2 (es) |
| CA (1) | CA2689930A1 (es) |
| CL (1) | CL2008001559A1 (es) |
| CO (1) | CO6241125A2 (es) |
| EC (1) | ECSP099773A (es) |
| IL (1) | IL202316A0 (es) |
| MX (1) | MX2009013130A (es) |
| PE (1) | PE20090319A1 (es) |
| RU (1) | RU2009148865A (es) |
| TW (1) | TW200904422A (es) |
| WO (1) | WO2008153792A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009148866A (ru) | 2007-06-01 | 2011-07-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| AU2009313527A1 (en) * | 2008-11-06 | 2010-05-14 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| BR112017015693A2 (pt) | 2015-02-03 | 2018-03-20 | Pfizer | ciclopropabenzofuranil piridopirazinadionas |
| TWI803570B (zh) * | 2018-02-01 | 2023-06-01 | 日商日本香煙產業股份有限公司 | 含氮雜環醯胺化合物以及其醫藥用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9205811A (pt) * | 1991-03-28 | 1994-06-28 | Pfizer | Derivados heterociclicos de aminas ciclicas |
| EP1603548A4 (en) | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| CA2532207A1 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| WO2006001877A2 (en) | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| EP1750719A2 (en) | 2004-05-19 | 2007-02-14 | Boehringer Ingelheim International GmbH | Treatment of diseases associated with altered level of amyloid beta peptides |
| JP4101852B2 (ja) * | 2004-05-26 | 2008-06-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド化合物 |
| EP1650183A1 (en) | 2004-10-21 | 2006-04-26 | Cellzome Ag | (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy |
| KR20080069221A (ko) * | 2005-11-24 | 2008-07-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모르폴린 타입의 신나미드 화합물 |
| US20070117839A1 (en) * | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
-
2008
- 2008-05-28 AU AU2008263206A patent/AU2008263206A1/en not_active Abandoned
- 2008-05-28 MX MX2009013130A patent/MX2009013130A/es unknown
- 2008-05-28 JP JP2010510315A patent/JP2010529014A/ja not_active Withdrawn
- 2008-05-28 BR BRPI0812491-4A2A patent/BRPI0812491A2/pt not_active Application Discontinuation
- 2008-05-28 EP EP08767901A patent/EP2164852A2/en not_active Withdrawn
- 2008-05-28 CA CA2689930A patent/CA2689930A1/en not_active Abandoned
- 2008-05-28 CN CN2008801013158A patent/CN101932578A/zh active Pending
- 2008-05-28 KR KR1020097027039A patent/KR20100021633A/ko not_active Application Discontinuation
- 2008-05-28 WO PCT/US2008/006733 patent/WO2008153792A2/en active Application Filing
- 2008-05-28 RU RU2009148865/04A patent/RU2009148865A/ru unknown
- 2008-05-28 US US12/600,910 patent/US8580956B2/en not_active Expired - Fee Related
- 2008-05-28 AR ARP080102243A patent/AR066151A1/es not_active Application Discontinuation
- 2008-05-28 PE PE2008000911A patent/PE20090319A1/es not_active Application Discontinuation
- 2008-05-29 CL CL2008001559A patent/CL2008001559A1/es unknown
- 2008-05-29 TW TW097119966A patent/TW200904422A/zh unknown
-
2009
- 2009-11-24 IL IL202316A patent/IL202316A0/en unknown
- 2009-11-30 EC EC2009009773A patent/ECSP099773A/es unknown
- 2009-12-01 CO CO09137088A patent/CO6241125A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20090319A1 (es) | 2009-03-27 |
| CN101932578A (zh) | 2010-12-29 |
| CL2008001559A1 (es) | 2008-12-05 |
| US20100255005A1 (en) | 2010-10-07 |
| TW200904422A (en) | 2009-02-01 |
| AU2008263206A2 (en) | 2010-01-21 |
| WO2008153792A3 (en) | 2009-05-07 |
| BRPI0812491A2 (pt) | 2014-12-02 |
| AU2008263206A1 (en) | 2008-12-18 |
| US8580956B2 (en) | 2013-11-12 |
| RU2009148865A (ru) | 2011-07-20 |
| CA2689930A1 (en) | 2008-12-18 |
| AR066151A1 (es) | 2009-07-29 |
| ECSP099773A (es) | 2009-12-28 |
| KR20100021633A (ko) | 2010-02-25 |
| IL202316A0 (en) | 2010-06-30 |
| EP2164852A2 (en) | 2010-03-24 |
| JP2010529014A (ja) | 2010-08-26 |
| WO2008153792A2 (en) | 2008-12-18 |
| MX2009013130A (es) | 2010-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6241125A2 (es) | Moduladores de gamma secretasa | |
| AR050188A1 (es) | Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
| EA200702470A1 (ru) | Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов | |
| AR047706A1 (es) | Inhibidores de polimerasa viral | |
| AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| AR056532A1 (es) | Moduladores 3-amino-tetrahidro-indazolil cannabinoides sustituidos | |
| CO6241123A2 (es) | Moduladores de la gamma secretasa | |
| AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
| AR054814A1 (es) | Derivados de piridazina | |
| CO6150160A2 (es) | Derivados de morfolino pirimidina utiles en el tratamiento de desordenes proliferativos | |
| CO5630029A2 (es) | Derivados de indol e indolina sustituidos | |
| DK2137143T3 (da) | Pleuromutilinderivater til behandling af sygdomme medieret af mikroorganismer | |
| CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| BRPI0517622A (pt) | imidas n-substituìdas como iniciadores de polimerização | |
| AR052066A1 (es) | Derivados de ciclohexano | |
| AR078538A1 (es) | Pirroles e imidazoles sustituidos como ligandos del receptor de estrogenos | |
| ES2294313T3 (es) | Derivados de piridina como moduladores del receptor cb2. | |
| AR047606A1 (es) | 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |